Assessing the role of the triglyceride-glucose index in the diagnosis and risk stratification of acute cholecystitis: A retrospective study.
| Title: | Assessing the role of the triglyceride-glucose index in the diagnosis and risk stratification of acute cholecystitis: A retrospective study. |
|---|---|
| Authors: | Keyif MF; Department of General Surgery, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Türkiye.; Bolat F |
| Source: | Medicine [Medicine (Baltimore)] 2026 Feb 06; Vol. 105 (6), pp. e47491. |
| Publication Type: | Journal Article; Observational Study |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins |
| MeSH Terms: | Triglycerides*/blood ; Cholecystitis, Acute*/diagnosis ; Cholecystitis, Acute*/blood ; Blood Glucose*/analysis; Biomarkers/blood ; Risk Assessment/methods ; C-Reactive Protein/analysis ; Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Severity of Illness Index ; ROC Curve ; Leukocyte Count |
| Abstract: | Accurate severity assessment is crucial in acute cholecystitis, yet commonly used inflammatory markers such as C-reactive protein, white blood cell count, and bilirubin have limited predictive accuracy. The triglyceride-glucose (TyG) index has emerged as a potential biomarker reflecting metabolic stress and inflammation. This retrospective observational study included 134 patients admitted with acute cholecystitis between 2020 and 2024. Disease severity was classified according to the Tokyo Guidelines 2018, and patients were grouped as non-severe (mild-moderate) or severe. Laboratory parameters obtained at admission were analyzed, and the TyG index was calculated as ln (fasting triglyceride × fasting glucose/2). Univariate and multivariable logistic regression analyses and receiver operating characteristic curve analysis were performed. Of the 134 patients, 26 (19.4%) had severe acute cholecystitis. Median fasting glucose (P = .031) and TyG index values (P = .029) were higher in the severe group, while triglycerides, C-reactive protein, white blood cell count, and bilirubin showed no significant differences. The TyG index was associated with severe disease in univariate analysis (odds ratio: 1.62; 95% confidence interval: 1.05-2.49; P = .028), but not after multivariable adjustment (P = .17). Receiver operating characteristic analysis demonstrated an area under the curve of 0.79 (95% confidence interval: 0.71-0.87; P |
| Competing Interests: | The authors have no funding and conflicts of interest to disclose. |
| References: | Front Endocrinol (Lausanne). 2024 May 23;15:1400448. (PMID: 38846493); Sci Rep. 2025 Jan 22;15(1):2745. (PMID: 39838034); Gut Liver. 2012 Apr;6(2):172-87. (PMID: 22570746); J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):55-72. (PMID: 29045062); Adv Lab Med. 2021 Jul 9;2(3):352-372. (PMID: 37362415); Front Public Health. 2024 May 31;12:1351884. (PMID: 38883189); BMC Med. 2020 Nov 25;18(1):361. (PMID: 33234146); Cardiovasc Diabetol. 2025 Jan 13;24(1):12. (PMID: 39806394); Lipids Health Dis. 2020 Jun 2;19(1):121. (PMID: 32487177); J Atheroscler Thromb. 2021 Nov 1;28(11):1175-1194. (PMID: 33191314); World J Emerg Surg. 2020 Nov 5;15(1):61. (PMID: 33153472); Diseases. 2023 Sep 28;11(4):. (PMID: 37873776); Biomedicines. 2021 Oct 01;9(10):. (PMID: 34680486); Rev Endocr Metab Disord. 2013 Mar;14(1):5-12. (PMID: 23306778); Front Endocrinol (Lausanne). 2024 Jul 11;15:1420999. (PMID: 39055055); J Hepatobiliary Pancreat Surg. 2007;14(1):15-26. (PMID: 17252293); Sci Rep. 2024 Aug 1;14(1):17778. (PMID: 39090272); Diabetes Metab J. 2017 Dec;41(6):430-437. (PMID: 29199410); Eur J Case Rep Intern Med. 2020 Jun 22;7(9):001764. (PMID: 32908838); Cardiovasc Diabetol. 2025 Aug 18;24(1):337. (PMID: 40826360); Cardiovasc Diabetol. 2023 Jul 15;22(1):180. (PMID: 37454147); Cardiovasc Diabetol. 2025 Aug 1;24(1):313. (PMID: 40750895); BMC Cardiovasc Disord. 2024 Dec 20;24(1):723. (PMID: 39707186); J Ultrasound Med. 2025 May;44(5):807-816. (PMID: 39745905); Cureus. 2024 Oct 27;16(10):e72481. (PMID: 39600764); J Clin Med. 2024 May 03;13(9):. (PMID: 38731224); J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3957-e3968. (PMID: 34125886) |
| Contributed Indexing: | Keywords: TyG index; acute cholecystitis; biomarker; severity |
| Substance Nomenclature: | 0 (Triglycerides); 0 (Blood Glucose); 0 (Biomarkers); 9007-41-4 (C-Reactive Protein) |
| Entry Date(s): | Date Created: 20260206 Date Completed: 20260206 Latest Revision: 20260211 |
| Update Code: | 20260211 |
| PubMed Central ID: | PMC12885659 |
| DOI: | 10.1097/MD.0000000000047491 |
| PMID: | 41650061 |
| Database: | MEDLINE |
Journal Article; Observational Study